Drugs availabletotreat asthma have improved considerably over the pastthree decades and understanding of the disease process is continually improving. However, the incidence of asthma is increasing and the cause(s) of this increase are not yet identified. Asthma is often underdiagnosed and undertreated. Poor compliance with medication is also an important consideration in how effective management strategies can be. The aim of current asthma treatment, according to the Global Initiative for Asthma (GINA), is to control the disease. However, two surveys, one in Europe and the other in the U.S.A. indicate that the objectives of treatment guidelines are not being met. Patients were shown to experience high rates of exacerbations and require many doses of reliever medication.There was also a large difference between patient and physician perceptions of treatment--this needs to be countered b/improved education for both the general public and healthcare professionals. Fo:moterol, which is the only/~2-agonist to possess both fast-and longacting properties, may help to improve patient compliance by allowing a single inhaler to be used for both maintenance and as-needed therapy. However, although formote:ol is already widely used as maintenance therap)4, currenttreatment guidelines do not include the use of formoterol as first-line reliever medication. Evidence is increasing to support asneeded use and a large, randomized effectiveness stud), in 18 000 patients across the world is ongoing to assess the safety and efficacy offormoterol as needed in a real-life setting.The results from the Real-Life Effectiveness of Oxis®Turbuha -let ® (RELIEF)study should help to establish the position of formoterol as an effective fi rst-line reliever medication and ultimately lead to the inclusion offormoterol as needed in treatment guidelines.
INTRODUCTION
Understanding of the pathophysiology of asthma is improving all the time and more is now known about the underlying inflammatory processes that result in symptoms and acute attacks. Although treatment of asthma has advanced over the past 30 years due to the availability of drugs to treat symptoms (e.g. short-acting/32-agonists) and inflammation (e.g. inhaled corticosteroids), the prevalence of asthma has increased over the past two decades (I,2). Allergen exposure and parental smoking have both been identified as risk factors but the impact of air pollution has not been proven.
The Global Initiative for Asthma (GINA) is a project conducted in collaboration with the National Heart, Lung and Blood Institute and the World Health Organization with the aim of helping healthcare professionals to reduce asthma prevalence, morbidity and mortality.
Correspondence should be addressed to: R. Pauwels, Department of Respiratory Diseases, University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Fax: (+32) 9 2402341; E-mail: romain.pauwels@rug.ac.be Although GINA produces guidelines for asthma diagnosis and treatment, it is also important not to forget patient needs in working towards the optimum treatment strategy Patients are not so concerned with clinical measures such as peak flow measurements or forced expiratory volume in I second (FEVi)--for patients, the main aim is to have a treatment strategy that allows them to live normal lives with minimum interference in everyday activities.
The GINA treatment guidelines are currently being updated, and any changes to current guidelines will be based on strong evidence of efficacy, safety, comparison with other therapies and cost-effectiveness. As it has now been suggested that many meta-analyses have serious methodological flaws, it may be better for such evidence to be obtained from large randomized studies (3) .
Currently, short-acting/~2-agonists are placed as reliever medication for symptom control. In contrast, fl2-agonists with long-acting properties, formoterol and salmeterol, are recommended only as maintenance therapy in moderate to severe patients poorly controlled on inhaled corticosteroids. Formoterol differs from all other #2-agonists, including salmeterol--it has not only a long duration of action but also a fast onset, and is therefore suitable for use as needed as well as in regular therapy.
GINA GUIDELINES FOR THE TREAT MENT OF ASTHMA
The GINA guidelines state that the goal of asthma therapy should be to" eliminate all symptoms, including those experienced at night-time; prevent exacerbations and minimize need for as-needed #2-agonist therapy; prevent limitation of activities; minimize side effects from treatment; and provide the patient with near normal lung function (4). However, asthma prevalence is increasing, particularly in children, and it is often underdiagnosed and undertreated. Treatment guidelines stress the importance of controlling inflammation, in particular with inhaled corticosteroids, and emphasis is placed on gaining control of symptoms promptly and stepping down treatment when control has been achieved. The use of long-acting #2-agonists with low-dose inhaled corticosteroids is an effective alternative to increasing the dose of corticosteroids prescribed for patients with moderate persistent asthma (5) .
The Asthma Insights and Reality in Europe (AIRE) study was a large survey carried out in seven countries across Europe (6) . Over 2800 asthmatic adults and children were questioned about their asthma status and treatment. Current asthma (defined as physician diagnosed with symptoms within the last 12 months) was found to be prevalent in 3488 out of 73 880 households screened.
When patients were questioned about their disease management, it was clear that treatment of asthma in Europe falls well short of the goals for long-term management established by GINA. Over one-third of children and half of all the adults surveyed had daytime symptoms at least once per week and only 39.5% of children and 55% of adults reported ever having had a lung function test performed by their doctor. Other findings are summarized inTable I.
Patients were classified as having mild intermittent, mild persistent, moderate persistent or severe persistent asthma according to the frequency and severity of symptoms reported. When questioned about their disease control, patients felt that their asthma was well managed and 76.5% of children and 65.9% of adults said they had either no symptoms or mild asthma during the past 4 weeks. However, some of the patients who felt that their disease was either well-or completely-controlled were actually assessed as having severe persistent asthma (Fig. I) .
Many factors were felt to contribute to the difference between patient perception and the reality of asthma control. Not only do patients underestimate the severity of their disease, they also overestimate the degree to which their asthma is controlled. Patients, thus, accept a lower degree of control than is achievable with current treatment strategies. Furthermore, this is compounded by physicians, as many trust the patients'own perception of their disease state and do not monitor the condition closely by adequate history taking and performing regular lung function tests.
A similar survey in the U.S.A.--Asthma in America (AIA)~cluestioned over 2500 adults and children and found similar results (7) . Patients were poorly controlled, with many exacerbations and a high level of lost work or school days. Sleep disruption, due to breathing problems at least once per week, was reported by 30% of patients and 48% said that asthma limits their ability to take part in sports or recreation. Other results are summarized inTable 2. Even though comprehensive treatment guidelines are available, many patients and their families suffer to an unnecessary degree due to morbidity associated with their asthma. Additionally, 47% of patients used their reliever medication daily, including 74% of patients with severe persistent and 21% with mild intermittent asthma. According to the guidelines, this level 
FORMOTEROLmPOSITION IN CURRENTAND FUTURE GUIDELINES
Formoterol is widely accepted to have a unique position as the only fl2-agonist with both fast-and long-acting properties. In current guidelines, fl2-agonists with a long-acting profile, including formoterol, are first-choice therapies for combination with low-to-moderate dose inhaled corticosteroids in moderate to severe asthma; data have shown this to be an effective choice, which is well tolerated in patients (5) . Formoterol is also currently used as add-on therapy to high-dose corticosteroids in patients with severe persistent asthma--in combination with other drugs--and can decrease the need for oral steroids by reducing the number of exacerbations (8) .
Although formoterol is licensed in many countries for as-needed therapy in patients already receiving it as maintenance therapy, it is not currently included as firstline reliever medication in management guidelines. However, evidence is increasing to support the use of formoterol in this and other areas of asthma treatment, including as-needed use in exercise-induced bronchoconstriction (EIB) and also for regular use in mild persistent asthma in addition to low doses of inhaled corticosteroids. In the Oxis ' g~ and Pulmicort ~ Turbuhaler 'g' in the Management of Asthma (OPTIMA) study the addition of formoterol 4.5 #g twice daily to budesonide resulted in fewer severe exacerbations and poorly controlled days in patients insufficiently controlled on budesonide 100 Itg twice daily compared with increasing the dose of budesonide to 200#g twice daily (9) . Formoterol 4.5 #g has been shown to provide more effective control, compared with terbutaline 500 itg, when used as first-line reliever medication in mild to moderate persistent asthma on maintenance therapy with inhaled corticosteroids (10) . Additionally, in patients with moderate to severe persistent asthma on regular treatment with the combination of inhaled corticosteroids and long-acting inhaled fl2-agonists, formoterol has been shown to be as good as terbutaline when used as needed (11). In patients receiving regular twice-daily treatment with formoterol plus additional inhalations as needed, superior asthma control was shown in patients with moderate to severe asthma compared with salbutamol, twice daily plus as needed (12) . Furthermore, formoterol has been shown to be well tolerated, with side effects similar in nature and duration to other fl2-agonists (13) (14) (15) (16) .
In EIB, a number of studies have shown that formoterol produces a degree of bronchoprotection equivalent to terbutaline, but with a much longer duration (17-18). Although with continued use it is not clear whether the maximum duration of effect, i.e. 12 h, is maintained, formoterol does still provide significant protection, even after prolonged use. Health economics is also very important in deciding which treatment strategy is the most appropriate. Adding formoterol to inhaled corticosteroid therapy has been shown to be a cost-effective approach in the treatment of moderately asthmatic patients (19) . Furthermore, in the Tattersfield study (10) formoterol used as first-line reliever medication has been shown to generate cost savings compared with terbutaline, resulting from a decrease in the number of severe exacerbations experienced (20).
The available evidence supports the use of formoterol as needed in all types and severities of asthma.There is a suggestion that, as well as improving asthma control, it could also result in a decrease in healthcare utilization. This hypothesis has still to be tested in large studies reflecting true clinical practice. Many studies, with very specific inclusion and exclusion criteria, limit the type of patients included and it is not always possible to extrapolate the results observed to the general population. The Real-Life Effectiveness of Oxis c~ Turbuhaler ~' (RELIEF) study is an ongoing trial designed to present a comprehensive picture of formoterol used as needed. This large, open, randomized, parallel-group study in 18 000 patients across the world includes a broad range of patients and assesses the use of formoterol as needed in asthmatic patients over a 6-month period. Patients 6 years or older, with a diagnosis of asthma, and requiring fl2-agonist therapy for relief of symptoms, were randomized to receive their usual maintenance treatment plus either formoterol 4.5#g or salbutamol 200#g, both as needed. Patients with concurrent conditions, other than pregnancy or lactation, will be included.The study design is shown in Fig. 2 .
The study aims to determine the therapeutic outcome with formoterol as needed in a real clinical setting and patient population, i.e. the effectiveness of formoterol as first-~ine reliever medication. The primary clinical objective is to assess the safety of formoterol as needed by monitoring serious adverse events and discontinuations of therapy due to adverse events. The secondary objective is to compare the efficacy of formoterol with salbutamol by monitoring time to first exacerbation, which is defined as hospitalization due to deteriorating asthma, emergency treatment due to asthma, a requirement for oral steroids lasting at least 5 days or a need to increase maintenance therapy due to worsening asthma. Other efficacy parameters to be collected are: number of exacerbations; use of as-needed medication; and number of days with asthma. The study will also include data on health economics including healthcare resource utilization and the number of days patients are incapable of conducting their usual activities.
CONCLUSIONS
Currently available data suggest that formoterol is an effective and well-tolerated treatment option in patients with asthma, in both as-needed and regular treatment. The RELIEF study should help to establish the place of formoterol in asthma management, ultimately leading to the inclusion of formoterol in treatment guidelines for use as needed in all patients with asthma. Formoterol has been shown to be effective in asthma of all severities and with its fast onset and long duration of action provides additional benefits compared with other /~2-agonists. It is well tolerated in high doses and suitable for use in mildly asthmatic patients and in the treatment of acute attacks. Furthermore, for patients requiring both maintenance and reliever therapy, formoterol could be used in both circumstances, reducing the number of inhalers necessary whilst maintaining good asthma control.
